Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Ecstacy Ingredient May Promote Cooperation

By Society for Neuroscience | November 21, 2018

The recreational drug known as ecstasy or molly may help people regain trust in others after being betrayed, suggests results of a controlled laboratory study, published in JNeurosci, of healthy men given a pure form of the substance. The drug is currently being assessed for its potential as a supplemental treatment for post-traumatic stress disorder.

Anthony Gabay and colleagues conducted a neuroimaging study of 3,4-methylenedioxy-methamphetamine (MDMA), a drug known to affect interpersonal interactions. The researchers specifically explored MDMA’s influence on social decision-making and the underlying brain activity.

Male participants were randomly assigned to receive MDMA or a placebo and then played a game in which the participant and a second player could either work together or against each other. Those in the MDMA group were more likely to choose to cooperate with an opponent who had betrayed them but otherwise proved to be trustworthy. This behavioral shift was not observed during interactions with untrustworthy opponents, indicating the effect of MDMA is sensitive to the other player’s behavior. Finally, the researchers report altered activity in brain regions involved in the processing of social information.


Filed Under: Neurological Disease

 

Related Articles Read More >

Novo Nordisk in the Drug Discovery & Development Pharma 50
Novo Alzheimer’s trial disappoints as amycretin shines
Shifting mindsets all around: clinical thinking about Alzheimer’s disease moves from symptoms treatment toward earlier intervention and prevention
Quanterix VP: Why biomarkers are no longer supplemental
Texas sues Kenvue claiming it hid link between Tylenol and autism
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE